Latest Depakote Stories
The law firm of Hissey Kientz, LLP is announcing the launch of its new website, Depakote Birth Defects Lawsuits (http://www.depakotelawsuitsbirthdefects.com/).
A new study published by has indicated that infants exposed to antiepileptic drugs, such as Depakote, during pregnancy may have an even higher risk of developing serious birth defects.
The law firm of Atkins & Markoff, a team of Oklahoma defective drug attorneys, hereby announces that the firm is reviewing claims free of charge regarding Depakote birth defects along with a full Depakote resource at http://www.atkinsandmarkoff.com.
Anticonvulsant medications such as Depakote are being found to possibly cause birth defects according to recent studies.
Researchers at the University of Groningen, in the Netherlands, have uncovered that exposure to Valproic acid in fetuses can lead to severe birth defects. Valproic acid is a common ingredient in anticonvulsant drugs such as Depakote.
As more victims of Depakote use during pregnancy speak out about the birth defects that have affected the lives of their families, Depakote attorneys working with the Consumer Justice Foundation website http://www.depakotebirthinjury.com are trying to recoup compensation for the life long medical care that will be required to treat children born with skeletal defects.
As lawsuits against the makers of the epilepsy drug Depakote begin to surface in the United States, Depakote lawyers begin to consult with families of birth defect victims about possible Depakote lawsuits.
The prescription drug Depakote is currently the most prescribed branded treatment for patients with mania associated with bipolar disorder as well as for the treatment of epilepsy.
The US Food and Drug Administration has issued a warning to health care professionals and patients about the potential increased risk of birth injuries and birth defects when valproate sodium and related products (e.g. Depacon, Depakote or Stavzor) are used by mothers during pregnancy.
ABBOTT PARK, Ill., Jan. 27 /PRNewswire-FirstCall/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2009. Diluted earnings per share, excluding specified items, were $1.18, reflecting 11.3 percent growth, at the high end of Abbott's previous forecast.